Astex Therapeutics Ltd.'s recent flurry of dealmaking "suggests a recognition by the pharmaceutical industry that high throughput screening has not been successful," observes Astex's chief executive Tim Haines, rather than some soaring demand for the specific tools that allow his firm and others within the structural biology space to reveal the nooks and crannies of active sites on the surface of protein targets. (See "Selling Structure," Start-Up, March 2001 Also see "Selling Structure" - Scrip, 1 March, 2001..)
Schering AG , the UK firm's most recent partner, "was looking through all the available technologies to help them...




